Maximum quantity allowed is 999
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 20MG |
€54.00
|
1 | 22 |
|
| 100MG |
€212.00
|
1 | 30 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | C2884 |
Purity / Analysis Method 
|
>98.0%(GC) |
| Molecular Formula / Molecular Weight | C__2__0H__1__4ClN__3 = 331.80 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 78351-75-4 |
| PubChem Substance ID | 253661527 |
| MDL Number | MFCD00209838 |
| Appearance | White to Light yellow powder to crystal |
| Purity(GC) | min. 98.0 % |
| NMR | confirm to structure |
| HS Number | 2933998090 |
1-(3-Chloroanilino)-4-phenylphthalazine (MY-5445) is a specific inhibitor of cyclic GMP (cGMP) phosphodiesterase type 5 (PDE5). MY-5445 inhibits platelet aggregation by increasing cGMP content.
Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation
M. Hagiwara, T. Endo, T. Kanayama, H. Hidaka, J. Pharmacol. Exp. Ther. 1984, 228, 467.
Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine
J. E. Souness, R. Brazdil, B. K. Diocee, R. Jordan, Br. J. Pharmacol. 1989, 98, 725.
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility
The requested SDS is not available.
Please Contact Us for more information.
A sample C of A for this product is not available at this time.
The requested analytical chart is not available. Sorry for the inconvenience.
